Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents

Chengliang Sun, Yao Cheng, Xiaojia Liu, Gefei Wang, Wenjian Min, Xiao Wang, Kai Yuan, Yi Hou, Jiaxing Li, Haolin Zhang, Haojie Dong, Liping Wang, Chenguang Lou, Yanze Sun, Xinmiao Yu, Hongbin Deng*, Yibei Xiao, Peng Yang

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

12 Downloads (Pure)


Programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1) have emerged as one of the most promising immune checkpoint targets for cancer immunotherapy. Despite the inherent advantages of small-molecule inhibitors over antibodies, the discovery of small-molecule inhibitors has fallen behind that of antibody drugs. Based on docking studies between small molecule inhibitor and PD-L1 protein, changing the chemical linker of inhibitor from a flexible chain to an aromatic ring may improve its binding capacity to PD-L1 protein, which was not reported before. A series of novel phthalimide derivatives from structure-based rational design was synthesized. P39 was identified as the best inhibitor with promising activity, which not only inhibited PD-1/PD-L1 interaction (IC50 = 8.9 nmol/L), but also enhanced killing efficacy of immune cells on cancer cells. Co-crystal data demonstrated that P39 induced the dimerization of PD-L1 proteins, thereby blocking the binding of PD-1/PD-L1. Moreover, P39 exhibited a favorable safety profile with a LD50 > 5000 mg/kg and showed significant in vivo antitumor activity through promoting CD8+ T cell activation. All these data suggest that P39 acts as a promising small chemical inhibitor against the PD-1/PD-L1 axis and has the potential to improve the immunotherapy efficacy of T-cells.

Original languageEnglish
JournalActa Pharmaceutica Sinica B
Issue number12
Pages (from-to)4446-4457
Publication statusPublished - Dec 2022


  • Co-crystal structure
  • Immunotherapy
  • PD-1/PD-L1
  • Small-molecule inhibitor


Dive into the research topics of 'Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents'. Together they form a unique fingerprint.

Cite this